<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621179</url>
  </required_header>
  <id_info>
    <org_study_id>IntegrinIVF</org_study_id>
    <nct_id>NCT00621179</nct_id>
  </id_info>
  <brief_title>Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF</brief_title>
  <acronym>IntegrinIVF</acronym>
  <official_title>Do Endometrial Implantation Markers Predict in Vitro Fertilization-Embryo Transfer Cycle Outcomes in Endometriosis Patients Pretreated With Leuprolide Acetate in Depot Suspension?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado Center for Reproductive Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Colorado Center for Reproductive Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective randomized trial evaluates whether one can predict which infertile women
      with endometriosis who are candidates for in vitro fertilization will benefit from prolonged
      therapy with a GnRH agonist by the determination of the absence of endometrial expression of
      the integrin, alpha v, beta 3 vitronectin. This is a prospective randomized trial in which
      all patients will undergo endometrial biopsy prior to initiation of ovarian stimulation for
      in vitro fertilization and then undergo randomization to a three month course of a depot
      preparation of the GnRH agonist leuprolide acetate in depot suspension prior to ovarian
      stimulation or standard therapy. prio
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See summary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing intrauterine pregnancy</measure>
    <time_frame>6-8 weeks after embryo transfer</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to controlled ovarian hyperstimulation</measure>
    <time_frame>Evaluated at time of embryo transfer</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Endometriosis</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Positive endometrial alpha v, beta 3 vitronectin expression. Standard controlled ovarian stimulation protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Positive endometrial alpha v beta 3 vitronectin expression, 3 months of leuprolide acetate in depot suspension administration prior to initiation of controlled ovarian stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Negative endometrial alpha v, beta 3 vitronectin and administration of leuprolide acetate in depot suspension for 3 months prior to initiation of controlled ovarian stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Negative endometrial alpha v, beta 3 vitronectin expression and standard controlled ovarian stimulation protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide acetate in depot suspension</intervention_name>
    <description>Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Depot Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide acetate</intervention_name>
    <description>leuprolide acetate 20 mcg subcutaneously twice daily for two days or 0.5 mg daily for 7 days prior to initiation of controlled ovarian stimulation</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide acetate</intervention_name>
    <description>Leuprolide acetate 20 mcg subcutaneously twice daily or 0.5 mg subcutaneously once daily prior to initiation of gonadotropin stimulation</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infertility

          -  Surgical diagnosis of endometriosis

          -  Normal ovarian reserve testing

          -  Regular menses

        Exclusion Criteria:

          -  Irregular menses

          -  Undiagnosed abnormal uterine bleeding

          -  Pregnancy

          -  Prior adverse reaction to any GnRH agonist

          -  Ovarian cystic or solid mass &gt; 3cm in mean diameter at study entry

          -  Use of a depot preparation of a GnRh agonist or any hormonal therapy for endometriosis
             within 6 months of study entry

          -  Current hepatic, renal, hematologic or psychiatric disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric S Surrey, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Colorado Center for Reproductive Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Colorado Center for Reproductive Medicine</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Surrey ES, Silverberg KM, Surrey MW, Schoolcraft WB. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis. Fertil Steril. 2002 Oct;78(4):699-704.</citation>
    <PMID>12372443</PMID>
  </reference>
  <reference>
    <citation>Lessey BA, Castelbaum AJ, Sawin SW, Buck CA, Schinnar R, Bilker W, Strom BL. Aberrant integrin expression in the endometrium of women with endometriosis. J Clin Endocrinol Metab. 1994 Aug;79(2):643-9.</citation>
    <PMID>7519194</PMID>
  </reference>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <last_update_submitted>February 13, 2008</last_update_submitted>
  <last_update_submitted_qc>February 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Eric Surrey, M.D.</name_title>
    <organization>Colorado Center for Reproductive Medicine</organization>
  </responsible_party>
  <keyword>Endometriosis,infertility,in vitro fertilization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

